Innovative clinical trials that enhance the understanding of cardiovascular disease and improve the care of patients.

 

Since its inception in 1984, the TIMI Study Group has been an Academic Research Organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease. We have led a wide array of trials, from phase I to phase IV, enrolling from less than 30 to more than 26,000 subjects, and with both industry and NIH support. Trials have been conducted in over 50 countries and at more than 5000 separate sites.

We investigate a broad array of therapeutic interventions in individuals across the spectrum of cardiovascular disease, ranging from prevention in those with risk factors, to emergent interventions in those with acute manifestations of disease. In addition, we have used our large database of clinical findings, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors.

By leading large-scale, international, randomized controlled trials of novel therapeutics and performing sophisticated analyses, we have been privileged to help shape the very practice of cardiovascular medicine for over a quarter of a century.

LEARN MORE

Academic Trial Leadership

TIMI Study Group investigators provide leadership for clinical trial design, execution, and analysis

Global Trial Operations

Global Trial Management, Biostatistics, Clinical Events Committee, Safety Desk, Medical Hotline

Core Labs

Biomarkers, Proteomics, Metabolomics, Genomics, ECG

Publications

Practice-changing contributions to the medical literature

Current and Recent Trials

Recent News and Publications

3/17/2017 - FOURIER primary results slide deck and NEJM paper now available!

3/12/2017 - TIMI Presentation Schedule See what TIMI Investigators are up to at ACC.17

3/14/2017 - New Publication: Koren MJ, Sabatine MS, Giugliano RP et al., Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. 2017 JAMA Cardiol.

2/1/2017 - New Publication: Giugliano RP et al., Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. 2017 Clin Cardiol.

11/12/2016 - AHA 2016 Scientific Sessions - TIMI Presentation Schedule

10/24/2016 - New Publication: Bonaca et al., Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial. 2016 JACC Cardiovasc Interv.

 

 More News